Relationship between TYMS and ERCC1 mRNA Expression and In Vitro Chemosensitivity in Colorectal Cancer

• Published in: Anticancer research 2011-11, Vol.31 (11), p.3843-3849
• Main Authors: YONG BEOM CHO, HYUK JUN CHUNG, WOO YONG LEE, SUNG HO CHOI, HEE CHEOL KIM, SEONG HYEON YUN, CHUN, Ho-Kyung
• Format: Article
• Language: English
• Subjects: 5-Fluorouracil; Adenocarcinoma - drug therapy; Adenocarcinoma - genetics; Adenocarcinoma - secondary; Adenocarcinoma, Mucinous - drug therapy; Adenocarcinoma, Mucinous - genetics; Adenocarcinoma, Mucinous - secondary; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; ATP; Biological and medical sciences; Carcinoma, Signet Ring Cell - drug therapy; Carcinoma, Signet Ring Cell - genetics; Carcinoma, Signet Ring Cell - secondary; Chemotherapy; Colorectal cancer; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - genetics; Colorectal Neoplasms - pathology; DNA-Binding Proteins - genetics; Drug Resistance, Neoplasm - genetics; Endonucleases - genetics; ERCC1 protein; Female; Fluorouracil - administration & dosage; Gastroenterology. Liver. Pancreas. Abdomen; Gene expression; Humans; Male; Medical sciences; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - genetics; Neoplasm Recurrence, Local - pathology; Organoplatinum Compounds - administration & dosage; oxaliplatin; Polymerase chain reaction; Prognosis; Real-Time Polymerase Chain Reaction; RNA, Messenger - genetics; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Thymidylate synthase; Thymidylate Synthase - genetics; Tumors
• ISSN: 0250-7005; 1791-7530

The aim of this study was to determine whether the relative mRNA expressions of the thymidylate synthase (TYMS) and the excision repair cross-complementing 1 (ERCC1) genes are associated with in vitro chemosensitivity to 5-fluorouracil (5-FU) and oxaliplatin in colorectal cancer, respectively. This study included 67 patients with pathologic TNM stage II, III, and IV. TYMS and ERCC1 mRNA expression was determined using real-time reverse transcriptase-polymerase chain reaction (RT-PCR). The chemosensitivity was examined using an ATP-based chemotherapy response assay. A high response was defined as a response producing ≥40% reduction in ATP. The mean level of TYMS mRNA expression in the groups with low and high response to 5-FU was 2.35×10(-3) ± 2.16×10(-3) 2(-(ΔCt)) and 4.54×10(-3) ± 2.46×10(-3) 2(-(ΔCt)), respectively. The mean level of ERCC1 mRNA expression in the groups with low and high response to oxaliplatin was 13.92×10(-3) ± 9.90×10(-3) 2(-(ΔCt)) and 23.59×10(-3) ± 5.88×10(-3) 2(-(ΔCt)), respectively. Groups with high response to 5-FU and oxaliplatin had significantly higher expression of TYMS and ERCC1 mRNA, respectively (p